NeOnc Technologies Holdings, Inc. will host an investor conference call and webcast on Wednesday, August 12, 2026, at 5:30 a.m. Pacific Time to present topline results from the Phase 2a portion of its NEO100-01 clinical trial, according to a press release from the company. The open-label study evaluates intranasal NEO100—a proprietary formulation of purified perillyl alcohol—in patients suffering from recurrent or progressive Grade III and Grade IV IDH1-mutant glioma.
Clinical Trial Scope and Executive Participants
The upcoming investor presentation will cover safety and efficacy observations gathered during the Phase 2a evaluation of the NEO100-01 trial, alongside planned regulatory next steps for the drug candidate, according to NeOnc Technologies. Management participants scheduled for the conference call include Amir Heshmatpour, executive chairman, president, and chief executive officer; Thomas C. Chen, MD, PhD, founder, chief medical officer, and chief scientific officer; Josh Neman, PhD, chief clinical officer; and Keithly Garnett, chief financial officer.
The trial tests intranasal delivery as a method to target central nervous system cancers. NeOnc designed its NEO drug development platform specifically to address historical difficulties in overcoming the blood-brain barrier, maintaining patent protections that extend to 2038, according to company statements.
Regulatory Status and Pipeline Context
Both NEO100 and a second candidate, NEO212, are currently advancing under U.S. Food and Drug Administration Fast-Track and Investigational New Drug status, according to company disclosures. NeOnc licenses its worldwide patent portfolio exclusively from the University of Southern California. This portfolio includes issued patents and pending applications covering NEO100, NEO212, and related family products designed for oncological and neurological indications.
Participants can access the webcast and subsequent question-and-answer session using the dial-in details provided through Globe Newswire and the company’s investor relations channels. The company reminds investors that clinical trial outcomes, including early-stage Phase 2a data, remain subject to audit, verification procedures, and future trial progression as outlined in filings with the Securities and Exchange Commission.
Related reading